BioVie Inc.
NCM: BIVILive Quote
📈 ZcoreAI Score
Our AI model analyzes BioVie Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get BIVI Z-Score →About BioVie Inc.
Healthcare
Biotechnology
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
📊 Fundamental Analysis
BioVie Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -80.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.35, BIVI currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $1.06 - $13.20).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$10.18M
Trailing P/E
--
Forward P/E
-0.31
Beta (5Y)
0.56
52W High
$13.20
52W Low
$1.06
Avg Volume
87K
Day High
Day Low